Go Pro
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free ALGS Stock Alerts

Aligos Therapeutics (ALGS) Competitors

Aligos Therapeutics logo
$6.36 0.00 (0.00%)
As of 11:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

ALGS vs. NRXP, UNCY, HURA, PEPG, and CUE

Should you buy Aligos Therapeutics stock or one of its competitors? MarketBeat compares Aligos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aligos Therapeutics include NRx Pharmaceuticals (NRXP), Unicycive Therapeutics (UNCY), TuHURA Biosciences (HURA), PepGen (PEPG), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry.

How does Aligos Therapeutics compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

In the previous week, Aligos Therapeutics had 2 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 3 mentions for Aligos Therapeutics and 1 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 1.87 beat Aligos Therapeutics' score of 0.45 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
NRx Pharmaceuticals Very Positive
Aligos Therapeutics Neutral

Aligos Therapeutics has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$1.23M128.10-$28.62M-$1.09N/A
Aligos Therapeutics$2.19M17.98-$24.19M-$8.69N/A

NRx Pharmaceuticals has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. NRx Pharmaceuticals' return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NRx PharmaceuticalsN/A N/A -202.92%
Aligos Therapeutics -1,919.68%-139.47%-90.88%

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NRx Pharmaceuticals has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the broader market.

NRx Pharmaceuticals presently has a consensus price target of $38.25, indicating a potential upside of 779.51%. Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 505.35%. Given NRx Pharmaceuticals' higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Aligos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NRx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Summary

Aligos Therapeutics beats NRx Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Aligos Therapeutics compare to Unicycive Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Aligos Therapeutics presently has a consensus price target of $38.50, suggesting a potential upside of 505.35%. Unicycive Therapeutics has a consensus price target of $21.75, suggesting a potential upside of 323.98%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than Unicycive Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Unicycive Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Unicycive Therapeutics had 6 more articles in the media than Aligos Therapeutics. MarketBeat recorded 9 mentions for Unicycive Therapeutics and 3 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.45 beat Unicycive Therapeutics' score of -0.10 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aligos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Unicycive Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Aligos Therapeutics has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos Therapeutics$2.19M17.98-$24.19M-$8.69N/A
Unicycive Therapeutics$680K206.63-$26.56M-$2.21N/A

Unicycive Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Unicycive Therapeutics' return on equity of -134.69% beat Aligos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aligos Therapeutics-1,919.68% -139.47% -90.88%
Unicycive Therapeutics N/A -134.69%-84.51%

Aligos Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aligos Therapeutics beats Unicycive Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to TuHURA Biosciences?

Aligos Therapeutics (NASDAQ:ALGS) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

In the previous week, Aligos Therapeutics had 1 more articles in the media than TuHURA Biosciences. MarketBeat recorded 3 mentions for Aligos Therapeutics and 2 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 1.68 beat Aligos Therapeutics' score of 0.45 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aligos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
TuHURA Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Aligos Therapeutics has higher revenue and earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos Therapeutics$2.19M17.98-$24.19M-$8.69N/A
TuHURA BiosciencesN/AN/A-$30.05M-$0.61N/A

TuHURA Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat TuHURA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aligos Therapeutics-1,919.68% -139.47% -90.88%
TuHURA Biosciences N/A -156.12%-105.38%

Aligos Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market.

Aligos Therapeutics presently has a consensus target price of $38.50, suggesting a potential upside of 505.35%. TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 270.37%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than TuHURA Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
TuHURA Biosciences
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Aligos Therapeutics beats TuHURA Biosciences on 12 of the 15 factors compared between the two stocks.

How does Aligos Therapeutics compare to PepGen?

PepGen (NASDAQ:PEPG) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

PepGen currently has a consensus target price of $11.50, indicating a potential upside of 354.73%. Aligos Therapeutics has a consensus target price of $38.50, indicating a potential upside of 505.35%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than PepGen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PepGen
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

PepGen has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. PepGen's return on equity of -59.89% beat Aligos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PepGenN/A -59.89% -49.62%
Aligos Therapeutics -1,919.68%-139.47%-90.88%

Aligos Therapeutics has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PepGenN/AN/A-$89.65M-$1.75N/A
Aligos Therapeutics$2.19M17.98-$24.19M-$8.69N/A

58.0% of PepGen shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PepGen has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the broader market.

In the previous week, PepGen and PepGen both had 3 articles in the media. PepGen's average media sentiment score of 0.93 beat Aligos Therapeutics' score of 0.45 indicating that PepGen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PepGen
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aligos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Aligos Therapeutics beats PepGen on 9 of the 15 factors compared between the two stocks.

How does Aligos Therapeutics compare to Cue Biopharma?

Aligos Therapeutics (NASDAQ:ALGS) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Aligos Therapeutics has higher earnings, but lower revenue than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos Therapeutics$2.19M17.98-$24.19M-$8.69N/A
Cue Biopharma$27.47M4.54-$26.60M-$5.58N/A

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 505.35%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Cue Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Cue Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Cue Biopharma had 5 more articles in the media than Aligos Therapeutics. MarketBeat recorded 8 mentions for Cue Biopharma and 3 mentions for Aligos Therapeutics. Cue Biopharma's average media sentiment score of 0.64 beat Aligos Therapeutics' score of 0.45 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aligos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cue Biopharma
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aligos Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market.

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 14.6% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cue Biopharma has a net margin of -59.65% compared to Aligos Therapeutics' net margin of -1,919.68%. Cue Biopharma's return on equity of -98.30% beat Aligos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aligos Therapeutics-1,919.68% -139.47% -90.88%
Cue Biopharma -59.65%-98.30%-53.69%

Summary

Cue Biopharma beats Aligos Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Aligos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALGS vs. The Competition

Export
MetricAligos TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$39.37M$3.64B$6.74B$12.51B
Dividend YieldN/A2.20%2.68%8.00%
P/E Ratio-0.7321.0126.9024.39
Price / Sales17.98314.09587.69117.46
Price / CashN/A61.9829.2249.36
Price / Book0.738.5010.926.33
Net Income-$24.19M$23.83M$3.58B$330.66M
7 Day Performance4.43%-3.45%-2.25%-0.84%
1 Month Performance20.45%6.33%3.08%-0.26%
1 Year Performance-26.81%48.44%26.23%19.99%

Aligos Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALGS
Aligos Therapeutics
3.2537 of 5 stars		$6.36
flat		$38.50
+505.3%		-23.9%$39.37M$2.19MN/A90
NRXP
NRx Pharmaceuticals
3.5218 of 5 stars		$4.16
+5.6%		$38.25
+819.5%		+29.3%$150.72M$1.23MN/A2
UNCY
Unicycive Therapeutics
3.0128 of 5 stars		$5.43
+1.3%		$21.75
+300.6%		+1.6%$148.73M$680KN/A9
HURA
TuHURA Biosciences
3.1555 of 5 stars		$2.24
-5.1%		$9.00
+301.8%		+3.5%$142.64MN/AN/AN/A
PEPG
PepGen
2.578 of 5 stars		$2.05
+8.5%		$11.50
+461.0%		+93.7%$141.80MN/AN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ALGS) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
They proved it worked in '76. Then buried it.
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
BNZI Lands a Zacks Upgrade!
Banzai International (NASDAQ: BNZI) just received a Zacks Rank 2 (Buy) upgrade, driven by improving earnings e...
Huge Alerts | Sponsoredtc pixel
American’s Biggest Threat Is Here
This feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...
Goldco Direct, LLC | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel